BioPharmSignal logoBioPharmSignal

Company Profile

AIM ImmunoTech Stock Price, News & Catalysts

Ticker:
AIM
Exchange:
AMEX
Sector:
Biopharma
Location:
United States

Stock performance

0.19 USD (+7.26%)

Close

Last updated: October 1, 2026

12M USD

Market cap

Why the stock is moving

The latest monitored company update is ā€œAIM ImmunoTech Highlights Recent Media Coverage of Ampligenā€™sĀ® Broad-Spectrum Antiviral and Biodefense Potential.ā€ The corresponding closing-price reaction is not yet available.

Company overview

Immunomodulator Development

AIM ImmunoTech is an immuno-pharma company developing Ampligen for oncology and selected infectious-disease applications. Its primary strategic focus is late-stage pancreatic cancer.

Ampligen

Ampligen, or rintatolimod, is a double-stranded RNA immunomodulator and selective TLR3 agonist. The candidate is designed to activate innate immune pathways and has been evaluated across multiple cancers, viral diseases and immune-related conditions.

Pancreatic Cancer Program

The Phase 2 DURIPANC study evaluates Ampligen with the anti-PD-L1 therapy durvalumab in metastatic pancreatic cancer. AIM is using the study and prior named-patient survival experience to inform the design of a planned pivotal Phase 3 program.

Future catalysts

  • DURIPANC Phase 2 clinical-benefit data in the first quarter of 2027.
  • DURIPANC Phase 2 overall-survival data in the third quarter of 2027.

Recent news

  1. 01

    AIM ImmunoTech Highlights Recent Media Coverage of Ampligenā€™sĀ® Broad-Spectrum Antiviral and Biodefense Potential

  2. 02

    AIM ImmunoTech Spotlights Growing Attention Around AmpligenĀ® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

  3. 03

    AIM ImmunoTech Discusses AmpligenĀ®ā€™s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video

  4. 04

    AIM ImmunoTech Highlights Ampligenā€™s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicinesā€™ Daraxonrasib

  5. 05

    AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of AmpligenĀ® in Pancreatic Cancer in New CEO Corner Video

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

TLSA

Tiziana Life Sciences

INDP

Indaptus Therapeutics

GOVX

GeoVax Labs

IDRA

Idera

NKTR

Nektar Therapeutics

INCY

Incyte

ADIL

Adial Pharmaceuticals

KZR

Kezar Life Sciences

Frequently Asked Questions

What is the current stock price of AIM ImmunoTech (AIM)?

AIM ImmunoTech (AIM) most recently closed at 0.19 USD, a +7.26% move versus the previous session.

What is the market cap of AIM ImmunoTech (AIM)?

AIM ImmunoTech currently has a market capitalization of 12M USD on BioPharmSignal.

What does AIM ImmunoTech do?

Immunomodulator Development AIM ImmunoTech is an immuno-pharma company developing Ampligen for oncology and selected infectious-disease applications. Its primary strategic focus is late-stage pancreatic cancer. Ampligen Ampligen, or rintatolimod, is a double-stranded RNA immunomodulator and selective TLR3 agonist. The candidate is designed to activate...

On which exchange is AIM stock listed?

AIM ImmunoTech (AIM) is associated with AMEX, United States, Biopharma.

What is PD-L1?

Pancreatic Cancer Program The Phase 2 DURIPANC study evaluates Ampligen with the anti-PD-L1 therapy durvalumab in metastatic pancreatic cancer.

Which conditions is AIM ImmunoTech targeting with PD-L1?

AIM ImmunoTech is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.

How does AIM ImmunoTech describe recent progress with PD-L1?

DURIPANC Phase 2 clinical-benefit data in the first quarter of 2027. DURIPANC Phase 2 overall-survival data in the third quarter of 2027.

What is durvalumab?

Pancreatic Cancer Program The Phase 2 DURIPANC study evaluates Ampligen with the anti-PD-L1 therapy durvalumab in metastatic pancreatic cancer.